Current problems in cancer. Case reports最新文献

{"title":"Primary neuroendocrine carcinoma of inguinal lymph node as a plausible entity: A case report","authors":"Jane Rhyu ,&nbsp;Saeed Sadeghi ,&nbsp;Jonathan C. King ,&nbsp;Steven D. Hart ,&nbsp;Jianyu Rao ,&nbsp;Run Yu","doi":"10.1016/j.cpccr.2023.100267","DOIUrl":"https://doi.org/10.1016/j.cpccr.2023.100267","url":null,"abstract":"<div><p>We report primary neuroendocrine carcinoma (NEC) of the inguinal lymph node (LN) as a plausible clinical entity. Though previously controversial and suspected to alternatively represent an atypical presentation of LN metastasis from an unknown primary, we now report the third case of isolated inguinal LN NEC. The cases strongly support this diagnosis as a separate clinical entity with indolent behavior, unlike NEC that has metastasized to the LN. Our patient was a 68-year-old female who presented with an isolated left 4 cm enlarged inguinal LN. A core needle biopsy of the mass demonstrated cores of soft tissue that were diffusely infiltrated by loosely cohesive neoplastic cells in streaming cords and clusters. The cells were hyperchromatic, enlarged, and exhibited very high nucleus to cytoplasm ratio with prominent nuclear crowding, vesicular chromatin, inconspicuous to rare nucleoli, and scant cytoplasm. Mitotic activity was robust. Immunohistochemistry staining showed positivity for synaptophysin with Ki67 &gt;80 % but was not supportive of lymphoma or Merkel cell carcinoma. The cytological diagnosis was metastatic small cell NEC. FDG-PET/CT showed intense FDG avidity of the left inguinal LN without any evidence of potential primary malignancy or distant metastatic disease. Based on 2 previous case reports with favorable outcomes, we considered primary inguinal LN NEC as a plausible diagnosis. The patient underwent surgical resection with surgical histology confirming small cell NEC in LN, and systemic therapy and radiation therapy were held off. Postoperatively, the patient has remained disease-free for 16 months. Recognition of this clinical entity is important as it carries favorable prognosis with surgery as first line therapy. Primary inguinal LN NEC should be considered in the differential diagnosis of NECs in an inguinal LN.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621923000510/pdfft?md5=cac9a80b8b9cc214672f525a981974e7&pid=1-s2.0-S2666621923000510-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138390523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Testicular seminoma relapse to the adrenal glands 25 years after primary diagnosis: A case report","authors":"Christine Federspiel Secher ,&nbsp;Thomas Wagner ,&nbsp;Anand Chainsukh Loya ,&nbsp;Gedske Daugaard ,&nbsp;Jakob Lauritsen","doi":"10.1016/j.cpccr.2023.100266","DOIUrl":"https://doi.org/10.1016/j.cpccr.2023.100266","url":null,"abstract":"<div><p>Testicular seminoma is a frequent tumor in young men, and most patients are cured after primary treatment. Relapse of the disease typically occurs within the first two years and late relapse after more than 5 years is only seen in around 4 %. The predominantly site of relapse is the retroperitoneal space, and non-pulmonary metastases such as adrenal metastases are rarely seen. We here report an exceedingly unusual case of seminoma relapse with bilateral adrenal metastases 25 years after diagnosis.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621923000509/pdfft?md5=cab7ad2c3382d84ca2fdf93c6aa8ac36&pid=1-s2.0-S2666621923000509-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134656525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A rare type of primary CD19-negative diffuse large B-cell lymphoma presenting as an infraorbital mass in the maxillary sinus","authors":"Nabil El Hage Chehade ,&nbsp;Dina Elantably ,&nbsp;Sara Ghoneim ,&nbsp;Fnu Raja ,&nbsp;Kyle Hunter ,&nbsp;William Tse","doi":"10.1016/j.cpccr.2023.100265","DOIUrl":"https://doi.org/10.1016/j.cpccr.2023.100265","url":null,"abstract":"<div><p>A 38-year-old male recently diagnosed with acute on chronic rhinosinusitis and orbital cellulitis presented with a right painful infraorbital mass and swelling. Fine needle aspiration of the mass demonstrated atypical lymphoid infiltrate highly suggestive of lymphoma. Flow cytometry and immunophenotypic analysis detected an abnormal lymphocytic population characterized by positive CD20, CD38, and CD10, however, the CD19 marker was negative. Whole-body positron emission tomography showed a sizeable hypermetabolic mass centered at the right maxillary sinus, extending into the right orbit, and several hypermetabolic lymph nodes in the right neck. A diagnosis of high-grade CD19-negative DLBCL was made and the patient was initiated on R-HyperCVAD (Rituximab- cyclophosphamide, vincristine, Adriamycin, dexamethasone) chemotherapy protocol.</p><p>The diagnosis of paranasal lymphoma may remain elusive for months leading to delays in treatment, thus a high index of suspicion is warranted. The loss of CD19 expression in DLBCL represents a diagnostic challenge because this surface marker is widely used to gate the B cells for immunophenotyping and flow cytometry analysis. It also leads to therapeutic limitations to CD19 targeting therapies.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621923000492/pdfft?md5=052c87af88768f431e7873740c6e9ac9&pid=1-s2.0-S2666621923000492-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92073803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of hepatic dysfunction from crizotinib followed by treatment with entrectinib","authors":"Takahito Mizuno ,&nbsp;Satoshi Hagimoto ,&nbsp;Takumi Umemura ,&nbsp;Mariko Higashikawa ,&nbsp;Takamasa Sakai ,&nbsp;Kouichi Tanabe ,&nbsp;Fumiko Ohtsu ,&nbsp;Tetsuya Yamada ,&nbsp;Tomoki Kimura","doi":"10.1016/j.cpccr.2023.100262","DOIUrl":"https://doi.org/10.1016/j.cpccr.2023.100262","url":null,"abstract":"<div><h3>Background</h3><p>Information regarding the safety of entrectinib for previously treated patients and patients with hepatic dysfunction is limited. This is the first case report of treatment modification attributable to hepatic dysfunction caused by crizotinib.</p></div><div><h3>Patients</h3><p>A 76-year-old Japanese woman was referred to the Department of Respiratory Medicine and Allergy after a computed tomography (CT) scan at the time of thyroid surgery. The CT scan revealed an enlarged right upper lobe nodule. After careful examination, she was diagnosed with T3N2M1c stage IV ROS1-positive lung adenocarcinoma; therefore, crizotinib (500 mg/day) was prescribed. On day 861 of treatment, crizotinib was discontinued because of repeatedly observed increased aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels. Approximately 2 weeks after crizotinib was discontinued, treatment was restarted with entrectinib 600 mg/day.</p></div><div><h3>Conclusions</h3><p>Entrectinib was prescribed because crizotinib caused hepatic dysfunction; however, the patient experienced grade 3 neutropenia and the creatinine phosphokinase (CPK) levels increased. After the dose reduction, she was able to continue treatment safely, without further worsening of the primary tumor or hepatic dysfunction. Therefore, entrectinib may be an option for patients who need treatment modification because of crizotinib-induced hepatic dysfunction. Increased CPK is a previously unknown adverse event occurring with entrectinib. This information is essential to risk management plans involving this drug. Further information regarding increased CPK and rhabdomyolysis occurring in patients treated with entrectinib is needed.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49846525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Central nervous system manifestations as initial presentation of plasma cell disorders: Differential management of 3 cases based on disease extent","authors":"Kyle McGrath ,&nbsp;Graeme A. Fenton ,&nbsp;Robert P. Seifert ,&nbsp;Keith R. Peters ,&nbsp;John W. Hiemenz ,&nbsp;Erin A. Dean","doi":"10.1016/j.cpccr.2023.100247","DOIUrl":"10.1016/j.cpccr.2023.100247","url":null,"abstract":"<div><p>Central nervous system (CNS) manifestations of plasma cell neoplasms are exceedingly uncommon. CNS multiple myeloma (MM) carries a dismal prognosis, and limited evidence exists to guide management of these patients. We report on 3 adult patients with plasma cell neoplasms that presented with CNS manifestations. After summarizing their clinical presentation along with radiologic and pathologic findings, we focus on the patients’ differential management depending on extent of disease while reviewing the literature on frontline therapy in this rare disease scenario.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49354352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safe prolonged use of brentuximab vedotin in a patient with Classical Hodgkin Lymphoma on hemodialysis","authors":"Aimee Schad ,&nbsp;Abhinandan R Pakanati ,&nbsp;Susan Woelich ,&nbsp;Abhishek Chilkulwar","doi":"10.1016/j.cpccr.2023.100249","DOIUrl":"10.1016/j.cpccr.2023.100249","url":null,"abstract":"<div><p>Classical Hodgkin Lymphoma (cHL) is a B-cell derived lymphoma with excellent cure rates, however poor functional status or co-morbid conditions limit treatment options. Brentuximab vedotin (BV), a CD30 antibody drug conjugate, has an expanding role in cHL treatment. A 53-year-old man with multiple co-morbidities including end stage renal disease (ESRD) presenting with pancytopenia was found to have cHL. Not a candidate for intensive chemotherapy, he was safely maintained on intermittent BV for three years. Literature on prolonged BV use in hemodialysis is extremely limited. This case suggests BV as a safe treatment option for CD30 positive cHL in patients with ESRD on hemodialysis.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49373841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Malignant transformation of mature cystic teratoma involving bowel: A case report","authors":"Sarah Thappa ,&nbsp;Sara Spielman ,&nbsp;Naixin Zhang ,&nbsp;Janira Navarro Sanchez ,&nbsp;Ashlee Smith ,&nbsp;Richard Moore ,&nbsp;Rachael Rowswell-Turner ,&nbsp;Cynthia Angel ,&nbsp;Brent DuBeshter","doi":"10.1016/j.cpccr.2023.100261","DOIUrl":"10.1016/j.cpccr.2023.100261","url":null,"abstract":"<div><p>Mature cystic teratomas are common benign neoplasms of the ovary. These tumors rarely undergo malignant transformation, the most frequent transformation is to a squamous cell carcinoma. Malignant transformation carries a poor prognosis. Herein, we present a case of a patient with a pelvic mass whose initial biopsy showed a benign teratoma, but subsequently underwent malignant transformation with fistulation to the small and large bowel.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42490905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advanced EGFR-mutant NCSLC resistant to osimertinib therapy as a result of a novel CGN-RET fusion mutation with favorable response to combined osimertinib and selpercaptinib, case report","authors":"Hamid Mirshahidi ,&nbsp;Sue Min Sophia Kwon ,&nbsp;Alberto Romagnolo ,&nbsp;Kiwon Park ,&nbsp;Adam Hagele","doi":"10.1016/j.cpccr.2023.100246","DOIUrl":"10.1016/j.cpccr.2023.100246","url":null,"abstract":"<div><p>RET-fusions are a known cause of acquired osimertinib resistance in patients with advanced NSCLC. Herein we describe the case of a patient who developed resistance to osimertinib, via acquisition of a novel CGN-RET fusion mutation. She had a favorable response to treatment with RET-targeting TKI selpercatinib, in combination with osimertinib.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44804499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A unique case of protein-losing enteropathy in the setting of immune checkpoint inhibition case report","authors":"Ezra Bernstein ,&nbsp;James Weinberger ,&nbsp;Avi Baskin ,&nbsp;Eesha Balar ,&nbsp;Victor Adorno Febles ,&nbsp;Arjun V. Balar","doi":"10.1016/j.cpccr.2023.100252","DOIUrl":"10.1016/j.cpccr.2023.100252","url":null,"abstract":"<div><p>Protein-losing enteropathy (PLE) is a well described entity, typically associated with autoimmune disorders such as Systemic Lupus Erythematosus (SLE). However, there is only one prior case reported on the association between PLE and the use of immune checkpoint inhibitors. We describe a case of PLE presenting in a patient in their 70’s with muscle-invasive urothelial bladder cancer that developed while on treatment with pembrolizumab, radiation and gemcitabine for her cancer. The patient presented initially with progressive edema and hypoalbuminemia, and diffuse small bowel thickening on CT imaging without associated upper or lower gastrointestinal symptoms. Endoscopy with biopsy was performed demonstrating normal gastric and small bowel epithelium. A stool test for alpha-1-antitrypsin demonstrated increased clearance consistent with fecal protein loss and a diagnosis of PLE, presumed immune-related. She was promptly initiated on systemic corticosteroids with brisk resolution in her symptoms and normalization of serum albumin levels.</p></div><div><h3>Insights</h3><p>This case highlights a rare immune-related adverse event, PLE, that should be considered in patients who develop hypoalbuminemia and its clinical sequelae after immune checkpoint inhibition therapy without evidence of colitis.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43036372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Leptomeningeal carcinomatosis in a patient with PALB2-mutated pancreatic adenocarcinoma: A case report and review of the literature","authors":"Dylan D. Walker ,&nbsp;Benjamin G. Kubas ,&nbsp;Guy T. Clifton ,&nbsp;Jason K. Burris ,&nbsp;Matthew J. Rendo","doi":"10.1016/j.cpccr.2023.100251","DOIUrl":"10.1016/j.cpccr.2023.100251","url":null,"abstract":"<div><p>Pancreatic cancer remains an inauspicious malignancy with poor long-term outcomes. The majority of patients present with advanced disease; many suffer from consequences of local progression of disease, and survival rates remain unacceptably poor. Central nervous system (CNS) metastatic spread is uncommon, with leptomeningeal carcinomatosis or leptomeningeal disease (LMD) having seldom been described in the literature. Herein we report the case of a patient with metastatic PALB2-mutated pancreatic cancer who developed progressive neurologic symptoms from LMD after five years of treatment. This case and others suggest a possible link between pancreatic cancer with absent double-strand break DNA homologous recombination repair mechanisms and the development of leptomeningeal disease.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41532299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}